To include your compound in the COVID-19 Resource Center, submit it here.

Stanford launches cannabinoid company Katexco for inflammatory disorders

Stanford University professors launched Katexco Pharmaceuticals Corp. (Toronto, Ontario) to develop therapies that target

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE